Clinical Trial Detail

NCT ID NCT01130519
Title A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

papillary renal cell carcinoma

Therapies

Bevacizumab + Erlotinib

Age Groups: adult

No variant requirements are available.